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Abnormal NFkB activation has been implicated in
Alzheimer’s disease (AD). However, the signaling
pathways governing NFkB regulation and function
in the brain are poorly understood. We identify com-
plement protein C3 as an astroglial target of NFkB
and show that C3 release acts through neuronal
C3aR to disrupt dendritic morphology and network
function. Exposure to Ab activates astroglial NFkB
and C3 release, consistent with the high levels of
C3 expression in brain tissue from AD patients and
APP transgenic mice, where C3aR antagonist treat-
ment rescues cognitive impairment. Therefore, dys-
regulation of neuron-glia interaction through NFkB/
C3/C3aR signaling may contribute to synaptic
dysfunction in AD, and C3aR antagonists may be
therapeutically beneficial.
INTRODUCTION
Astroglia are responsible for diverse functions in the CNS and
play a crucial role in maintaining neuronal physiology. Astroglia
maintain glucose, ATP, and glutamate homeostasis; modulate
synaptic formation and function; and are an essential compo-
nent of the blood-brain barrier (Coulter and Eid, 2012; Lalo
et al., 2014; Seifert and Steinha¨user, 2013). In response to brain
insults such as injury, infection, or neurodegeneration, astroglia
become reactive, which results in the activation of immune me-
diators and release of proinflammatory cytokines (reviewed by
Kyritsis et al., 2014). A key regulator of inflammation in the pe-
ripheral system andCNS is the heterodimeric transcription factor
nuclear factor kB (NFkB) (reviewed by Baltimore, 2011; Oecking-
haus and Ghosh, 2009). Under normal conditions, NFkB is tightly
regulated by its inhibitor protein IkB, which sequesters NFkB in
the cytoplasm. Upon degradation of IkB, NFkB translocates tothe nucleus where it activates expression of kB target genes,
including its inhibitor IkBa (Chiao et al., 1994), which form an
autoinhibitory feedback loop that ensures proper silencing of
NFkB following each activation. Accordingly, deletion of IkBa
(Beg et al., 1995; Klement et al., 1996) or disruption of the kB
sites in the IkBa promoter (Peng et al., 2010; Shim et al., 2011)
leads to aberrant NFkB activation and a spectrum of immunolog-
ical phenotypes.
Activation of NFkB is associated with various neurodegenera-
tive conditions, including Alzheimer’s disease (Kaltschmidt et al.,
1997; Mori et al., 2010), Parkinson’s disease (Hunot et al., 1997),
and Huntington’s disease (Hsiao et al., 2013). Both neurotoxic
and neuroprotective roles have been proposed for NFkB, with
the outcome likely dependent on the timing, duration, and level
of activity (reviewed by Mattson et al., 2000; Mattson and
Meffert, 2006; Pizzi and Spano, 2006). Given the potential impor-
tance of aberrant NFkB activation in neuroinflammatory condi-
tions, it is important to clarify the signaling cascades mediating
its activity in neurons and glia and to understand the conditions
under which NFkB either attenuates or aggravates disease.
The complement pathway is an essential immune regulator of
host defense to infection, cell integrity, and tissue homeostasis in
the peripheral system (Holers, 2014; Ricklin and Lambris, 2013).
Full complement activation involves concerted actions of over 30
proteins that participate in three distinct pathways: classical,
alternative, and mannose-binding-lection. All converge on
the cleavage of the central complement protein C3 (Zipfel and
Skerka, 2009). In the CNS, complement factors such as C3a
and C1q have been shown to regulate synaptic refinement and
neuronal survival during development (Benoit and Tenner,
2011; Shinjyo et al., 2009; Stevens et al., 2007). However, little
is known about the mechanisms regulating complement expres-
sion and its influence on neuronal function and dysfunction in the
adult brain.
Here we examined the cell-specific effects of NFkB activation
in neurons and astroglia by deleting its inhibitor, IkBa, in these
cell types. We identify a novel neuron-glia interaction pathway
whereby astroglial NFkB activation and subsequent release ofNeuron 85, 101–115, January 7, 2015 ª2015 Elsevier Inc. 101
Figure 1. C3 Is Overexpressed in IkBa-Defi-
cient Astroglia
(A)QuantitativeRT-PCRmeasurementofC3mRNA
expression inhippocampalsamplesof2-month-old
Nestin-Cre; IkBafl/ (NcKO), CamKIIa-Cre; IkBafl/
(CcKO), and GFAP-Cre; IkBafl/ (GcKO) mice and
their littermate controls (Ctrl). n = 3/group/experi-
ment, Student’s t test.
(B) C3 protein levels in GcKO and Ctrl hippocampi
measured by ELISA. n = 6/group/experiment,
Student’s t test.
(C) C3 mRNA levels in WT and IkBa KO
primary neurons or astroglia. n = 3/group/experi-
ment, two-way ANOVA followed by pairwise
comparison.
(D) ELISA quantification of C3 protein levels in
conditioned media of WT or IkBa KO astroglial
cultures. n = 3/group/experiment, Student’s t test.
(E) C3 mRNA expression in WT or IkBa KO
astroglial cultures treated with different combina-
tions of TNF-a (50 ng/ml) or the NFkB inhibitor
JSH23 (20 mM). n = 3/group/experiment, three-
way ANOVA followed by pairwise comparison.
*p < 0.05; **p < 0.01; ***p < 0.001. See also
Figure S1.
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An NFkB/C3/C3aR Neuron-Glia Signaling Pathwaycomplement C3 acts through the neuronal C3a receptor to
impair dendritic structure and network function.
RESULTS
Complement Factor C3 Is an Astroglial Target of NFkB
We created a CNS-specific IkBa deletion (NcKO) by crossing an
IkBa floxed allele with a Nestin-Cre transgenic line (Lian et al.,
2012). Consistent with its role as a principal inhibitor of NFkB,
we found that deletion of IkBa was associated with sustained
NFkB activity (Lian et al., 2012). We performed expression
profiling of hippocampal samples taken from the NcKO mice
and their littermate controls to identify downstream targets acti-
vated by NFkB (Figure S1A available online). Among the many
genes identified, we found that complement factor 3 (C3), a cen-
tral molecule in the complement signaling pathway, was signifi-
cantly upregulated in the NcKO mice (Figure S1A; Figure 1A).
We and others have shown previously that astrocytes display
prominent NFkB activity (Herkenham et al., 2011; Lian et al.,
2012; Mao et al., 2009). Consistent with an astrocytic bias in
NFkB signaling, we found that IkBa, a known downstream target
of NFkB, was expressed at substantially higher levels in astroglia
than in neurons under both basal (5-fold) and tumor necrosis
factor a (TNF-a)-stimulated conditions (50-fold) (Figure S1B).
TNF-a induced drastic IkBa upregulation in astroglia but only
marginal induction in neurons (Figure S1B). These results estab-
lish that astroglia, rather than neurons, are the main site of IkBa
expression and NFkB activity.
The prominent NFkB response in astroglia suggests that
the rise in hippocampal C3 expression observed in the NcKO
mice likely originated from astroglia. To test this prediction, we
crossed the IkBa floxed allele with CaMKIIa-Cre (Dragatsis and
Zeitlin, 2000) or GFAP-Cre (Bajenaru et al., 2002) to create102 Neuron 85, 101–115, January 7, 2015 ª2015 Elsevier Inc.mice with selective IkBa deletion in neurons (CcKO) or in astro-
cytes (GcKO), respectively (Figure S1C). Astroglial deletion of
IkBa reduced the level of IkBa mRNA and protein by roughly
the same amount as the whole-brain knockout, confirming that
themajority of NFkBsignalingwas indeed localized to astrocytes
(Figures S1D and S1E). C3 mRNA expression in the astrocyte-
specific GcKO, but not in the neuron-specific CcKO, also
matched that of whole-brain NcKO (Figure 1A). ELISA analysis
confirmed elevation of C3 protein levels in the GcKO mice (Fig-
ure 1B). As with whole-brain IkBa deletion, no overt phenotypes
were detected in the GcKO mice (Figure S1F).
The C3 promoter contains two putative kB binding sites (Fig-
ure S1G) and is speculated to be an NFkB target (Moon et al.,
1999; Vik et al., 1991). To test whether C3 transcription is medi-
ated by direct binding of NFkB to theC3 promoter, we performed
chromatin immunoprecipitation in primary astroglial cultures
using an anti-p65 antibody to recover DNA bound to NFkB in
the presence and absence of TNF-a stimulation. PCR analysis
showed that although the kB-1 site was enriched in all immuno-
precipitates, the kB-2 site was enriched only upon TNF-a
stimulation (Figures S1G and S1H). Although the reason for the
differential response to TNF-a remains to be established, this
result validated C3 as a direct NFkB target in astroglia.
The GFAP-Cre line can evoke neuronal deletion of floxed
alleles (Bajenaru et al., 2002; Dro¨gemu¨ller et al., 2008), so we
employed a second strategy to confirm that astrocytes were
selectively responsible for C3 elevation following NFkB activa-
tion. We prepared primary astroglial and neuronal cultures
derived from germline IkBa knockout mice (KO) and their litter-
mate wild-type (WT) controls (Beg et al., 1995). In agreement
with the in vivo data, we detected 10-fold higher basal C3
mRNA levels in WT astroglial cultures compared with the WT
neuronal cultures (compare WT Astroglia with WT Neuron,
Neuron
An NFkB/C3/C3aR Neuron-Glia Signaling PathwayFigure 1C). Significantly, IkBa deletion did not affect C3 expres-
sion in neuronal cultures (compare KO Neuron with WT Neuron,
Figure 1C) but led to an approximately 3-fold further increase in
astroglia (compare KO Astroglia with WT Astroglia, Figure 1C).
Increased astroglial C3 in the absence of IkBa was further
confirmed by normalizing C3 mRNA with other housekeeping
genes (Figures S1I and S1J) and by measuring secreted C3 pro-
tein in conditioned media of WT and IkBa KO astroglial cultures
(Figure 1D).
To confirm that C3 overexpression in IkBa mutants is depen-
dent on NFkB, we applied the NFkB inhibitor JSH23 to WT and
IkBa KO primary astroglial cultures in the presence or absence
of TNF-a. We found that C3 mRNA levels were not affected by
JSH23 in WT cultures but that both basal and TNF-a-induced
C3 upregulation was potently blunted by JSH23 in IkBa KO as-
trocytes (Figure 1E). We noticed a small but significant increase
of C3 in WT cultures in response to TNF-a stimulation (Figure 1E,
WT,  versus + TNF-a). However, this pool was insensitive to
JSH23, suggesting that other transcriptional modulators, such
as C/EBP or mitogen-activated protein kinase, were responsible
for the increase (Maranto et al., 2008, 2011). Taken together, our
in vivo and in vitro data provide unequivocal support for the
hypothesis that astroglia, rather than neurons, are the principle
site of NFkB activation and primarily responsible for the NFkB-
dependent increase in C3.
Given that C3 is a central molecule in the complement
signaling cascade, we tested which complement pathway is
activated by C3 overexpression.Wemeasured themRNA of pro-
teins required for classical (C1q and C4) or alternative (Cfb and
Cfh) complement pathways in WT and IkBa-deficient astroglial
cultures (Figure S1K) and mouse brains (Figure S1L). We de-
tected upregulation of classical complement factors C1q and
C4 but not the alternative pathway factors Cfb or Cfh. These re-
sults suggest that astroglial NFkB/C3 promotes activation of the
classical complement pathway.
Astroglial NFkB/C3 Activation Leads to Impaired
Synaptic Density and Dendritic Morphology
We next wanted to explore what impact astrocytic C3 release
might have on the structure or function of neighboring neurons.
We employed a coculture system of primary WT or IkBa
knockout astroglia (WTAs or KOAs, respectively) with WT hippo-
campal neurons to measure synaptic density and dendritic
morphology in the presence or absence of astroglial NFkB acti-
vation. Double immunostaining of these cultures with NeuN/Iba1
(Figure S2A) or GFAP/Iba1 (Figure S2B) revealed that microglia
comprise less than 1% of the total cell population in both
neuronal and astrocytic cultures (Figure S2C), arguing against
a potential contribution of microglia in the culture system.
Synaptic density was evaluated by coimmunostaining for the
synaptic marker synaptophysin (Syn) and the dendritic microtu-
bule-associated protein 2 (MAP2) (Figure 2A). We found a signif-
icant reduction of synaptic density in WT neurons cocultured
with IkBa KO astroglia (Figure 2C). Further examination of excit-
atory and inhibitory synapses using vesicular glutamate trans-
porter 1 (VGluT1, Figure 2B) or vesicular g-aminobutyric acid
transporter (VGAT, Figure S2D), respectively, revealed a signifi-
cant reduction in excitatory but not inhibitory synapses (Fig-ure 2C). In addition, both total dendritic length (Figure 2D) and
dendritic complexity (Figures 2E and 2F) were reduced in neu-
rons plated with IkBa KO astrocytes.
To test that the neuronal phenotypes triggered by IkBa KO
astroglia were mediated through C3, we supplemented WT
neuronal monocultures with different doses (1, 2, and 5 mg/ml)
of recombinant C3 and determined the effect on neuronal
morphology. Similar to neurons cultured with KO astrocytes,
both the synaptic density (Figures 2G and 2H) and dendritic
complexity (Figures 2I and 2J) were reduced at all C3 concentra-
tions tested. Conversely, we tested whether immunodepletion of
C3 from conditioned medium derived from IkBa KO astroglia
would abrogate its impact on neuronal morphology. Neurons
treated with C3-depleted but not GFP-depleted medium main-
tained normal dendritic morphology (Figures S2H and S2I).
These experiments support a role for secreted C3 in mediating
the effects of astroglial NFkBactivation on neuronal morphology.
To corroborate these findings in vivo, we used adeno-associ-
ated virus (AAV) to sparsely label cortical neurons with GFP in
adult WT and astroglial IkBa-deficient (GcKO) mice (Figure 3;
Movie S1). We reconstructed the 3D structure of dendritic seg-
ments to perform an unbiased automatic classification of spine
types (mushroom, stubby, long-thin, and filopodia) (Figure 3A).
With the exception of filopodia, all other spine types (Figure 3C;
Figure S3B) as well as total spine density (Figure 3B; Figure S3A)
were significantly reduced in the GcKOmice without altering the
relative percentage of each spine type (Figure 3D; Figure S3C).
Neuronal Complement Receptor C3aR Mediates the
Effect of Astroglial NFkB/C3 Signaling
We next wanted to test whether the neuronal complement re-
ceptor was required to translate astrocytic C3 release into a
neuronal morphological response. Cleavage of C3 generates
C3a and C5a, which executes complement functions through
binding of its receptors C3aR and C5aR, respectively (Nataf
et al., 1999; Rahpeymai et al., 2006). C3aR and C5aR are both
G protein-coupled receptors expressed in many cell types,
including neurons (Be´nard et al., 2008; Gasque et al., 2000; Shin-
jyo et al., 2009). We tested whether C3aR or C5aRwere neuronal
mediators of the NFkB/complement pathway by treating neuron-
astrocyte cocultures with antagonists against C3aR (C3aRA) or
C5aR (C5aRA). We again used WT neurons cultured with either
WT or IkBa KO astrocytes in the presence or absence of these
complement receptor antagonists. Sholl analysis revealed that
blocking C3aR, but not C5aR, preserved dendritic branching
and spine density in the KOA cultures (Figures 4A and 4B;
Figures S4A–S4E). Although the C3aR antagonist increased
dendritic complexity in neurons culturedwith KO astrocytes (Fig-
ure 4B, KOA, DMSO versus C3aRA), it had an apparent opposite
effect on neurons cultured with WT astrocytes (Figure 4B, WTA,
DMSO versus C3aRA). These results suggest that although
excessive C3/C3aR activity is detrimental to neuronal health,
basal C3aR signaling might play a role in maintaining normal
dendritic extension.
C3aR is expressed in both neurons and astroglia, and, there-
fore, it is plausible that astroglial C3aR may have contributed
to the effects of C3aR manipulation in our coculture system.
To rule out this possibility, we tested whether loss of neuronalNeuron 85, 101–115, January 7, 2015 ª2015 Elsevier Inc. 103
Figure 2. Astroglial C3 Alters Synaptic and Dendritic Morphology
(A) Double immunostaining of wild-type or IkBa KO astroglia (WTA or KOA) cocultured neurons with anti-synaptophysin (Syn) and anti-MAP2 (MAP2) antibodies.
Scale bar, 10 mm.
(B) Same as (A) except that anti-VGluT1 (VGluT1) antibody was used instead of Syn. The images underneath each panel are enlarged views of the bracketed
areas. Scale bar, 10 mm.
(C) Quantification of the number of Syn+MAP2+, VGluT1+MAP2+, or VGAT+MAP2+ synaptic puncta per 10 mm of dendrite in WTA and KOA cocultured neurons.
nWTA Syn = 31, nKOA Syn = 28, nWTA VGluT1 = 57, nKOA VGluT1 = 52, nWTA VGAT = 45, and nKOA VGAT = 52 (Student’s t test).
(D) Quantification of total MAP2-positive dendritic lengths in WTA and KOA cocultured neurons. nWTA = 38 and nKOA = 42 (Student’s t test).
(E) Representative dendritic structure. Scale bar, 20 mm.
(legend continued on next page)
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Figure 3. Impaired Dendritic Morphology in
GcKO Mice
(A) Schematic of the steps taken for dendritic spine
analysis in vivo. Four-month-old littermate control
(Ctrl) and GcKOmouse brains were stereotaxically
injected with AAV-GFP virus followed by mea-
surement of spine density 3 weeks later. IMARIS
was used to reconstruct the 3D renderings of the
spines on dendrites based on confocal images
of GFP-positive neurons and to classify the four
spine types (mushroom, stubby, long-thin, and
filopodia). Scale bar, 5 mm.
(B) Total spine density in Ctrl and GcKO mouse
brains. nCtrl = 25 and nGcKO = 22.
(C) Density of each of the four spine types in Ctrl
andGcKOmouse brains. nCtrl = 39 and nGcKO = 31.
(D) Frequency of each spine type.
Dendritic segments were derived from 3 animals/
group, Student’s t test. *p < 0.05; **p < 0.01; ***p <
0.001. See also Movie S1 and Figure S3.
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An NFkB/C3/C3aR Neuron-Glia Signaling PathwayC3aR would abrogate dendritic phenotypes when cultured with
IkBa KO astrocytes. We again performed coculture experiments
with IkBa KO astrocytes but used neurons derived from WT
(C3aRWTN) or C3aR-null (C3aRKON) mice (Humbles et al.,
2000; Figures 4C and 4D). We found that dendritic complexity
in neurons cultured with IkBa KO astrocytes was preserved by
neuronal C3aR deletion (Figure 4D), therefore establishing a
definitive role of neuronal C3aR in the response to astroglial C3
release. Unlike with C3aRA treatment, although there is a trend
of reduction in dendritic extension in C3aR knockout neurons,
the difference did not reach statistical significance (compare
C3aRWTN WTAs with C3aRKON WTAs, Figure 4D). Possible
compensation resulting from germline C3aR deficiency may be
a contributing factor for the differences between pharmacolog-
ical inactivation and genetic ablation.
To provide in vivo evidence that C3aR is required for the
observed effects of astroglial NFkB activation, we treated WT(F) Quantification of dendritic complexity of WTA and KOA cocultured neurons by Sholl analysis. nWTA = 39
(G) Double-staining of Syn and MAP2 of WT neurons treated with vehicle (PBS) or 5 mg/ml C3. Scale bar, 10
(H) Quantified synaptic density of neurons treated with PBS or C3 at 1, 2, or 5 mg/ml. nPBS = 36, n1 mg/ml = 3
followed by Bonferroni post hoc analysis).
(I) Representative dendritic structures of WT neurons treated with PBS or 5 mg/ml C3. Scale bar, 20 mm.
(J) Dendritic complexity quantification of WT neurons treated with PBS or C3 at 1, 2, and 5 mg/ml. nPBS = 116, n
ANOVA followed by Bonferroni post-hoc analysis).
*p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S2.
Neuron 85, 101–11and GcKO mice systemically with C3aR
antagonist (Figures 4E and 4F). AAV was
again used to sparsely label cortical neu-
rons with GFP so spine density could
be measured following 3 weeks of antag-
onist or vehicle treatment. Although
C3aRA treatment had no significant ef-
fect onWTanimals (Figure 4F; Figure S4F,
Ctrl, DMSO versus C3RA), it completely
rescued spine density in GcKOmice (Fig-
ure 4F; Figure S4F, GcKO, DMSO versus
C3aRA). Taken together, these resultsdemonstrate that abnormal C3/C3aR signaling affects neuronal
morphology in vitro and in vivo.
The above studies identified a novel pathway by which astro-
glial NFkB activation leads to elevated complement signaling
and reduced synaptic and dendritic densities in vitro and in vivo.
These were correlated with neuronal circuitry deficits because
the IkBaGcKOmice exhibited an impaired hippocampal-depen-
dent contextual fear response (Figure 4G) and long-term potenti-
ation (LTP) of the Schaffer collateral pathway (Figure 4I). Consis-
tent with the rescue of dendritic morphology by C3aR blockade,
both the behavioral and synaptic plasticity deficits were attenu-
ated by C3aR antagonist treatment (Figures 4H and 4J).
Intraneuronal Calcium Mediates Neuronal Excitation
Downstream of C3aR
It has been reported that C3aR hyperactivation can mobilize
intracellular calcium in some cell types (Ahamed et al., 2004;and nKOA = 44 (two-way ANOVA).
mm.
3, n2 mg/ml = 37, and n5 mg/ml = 29 (one-way ANOVA
1 mg/ml = 66, n2 mg/ml = 53, and n5 mg/ml = 68 (two-way
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Figure 4. Neuronal C3aR Mediates Dendritic Morphology and Network Function
(A) Representative images of MAP2-positive dendritic structures in WTA or KOA cocultured neurons treated with DMSO or 1 mM C3aRA for 4 days. Scale bar,
20 mm.
(B) Sholl analysis of the dendritic complexity of WTA or KOA cocultured neurons treated with DMSO or C3aRA. nWTA DMSO = 47, nKOA DMSO = 55, nWTA C3aRA = 63,
and nKOA C3aRA = 57 (three-way ANOVA followed by pairwise comparison).
(C) Representative MAP2-positive dendrites of C3aR wild-type (C3aRWTN) or knockout (C3aRKON) neurons cocultured with IkBaWT or KO astroglia (WTA or
KOA). Scale bar, 20 mm.
(D) Sholl analysis of the dendritic complexity of WTA or KOA cocultured C3aRWTN or C3aRKON neurons. nC3aRWTN WTA = 46, nC3aRKOA WTA = 51, nC3aRWTN KOA =
44, and nC3aRKOA KOA = 46 (three-way ANOVA followed by pairwise comparison).
(E) Representative dendritic spines in 10-month-old Ctrl or GcKO mouse brains treated with DMSO or C3aRA (1 mg/kg i.p.) for 3 weeks. Scale bar, 10 mm.
(F) Quantification of spine density in Ctrl or GcKOmouse brains treated with DMSO or C3aRA. nCtrl DMSO = 69, nGcKO DMSO = 80, nCtrl C3aRA = 41, and nGcKO C3aRA =
43. Dendritic segments from 3 animals/group were selected for spine density quantification (two-way ANOVA followed by pairwise comparison).
(G) Reduced contextual freezing in GcKO mice. nCtrl = 14 and nGcKO = 18 (Student’s t test).
(H) Rescue of contextual memory defects of GcKOmice by C3aRA treatment. DMSO, vehicle treated controls. nCtrl DMSO = 6, nGcKO DMSO = 7, nCtrl C3aRA = 8, and
nGcKO C3aRA = 6 (two-way ANOVA followed by pairwise comparison).
(I) Slope of fEPSP in response to q burst stimulation delivered to the Schaffer collateral pathway from Ctrl or GcKO mice treated with DMSO or C3aRA.
(J) Quantification of the average fEPSP slope in the last 10 min. nCtrl DMSO = 6, nGcKO DMSO = 5, nCtrl C3aRA = 8, and nGcKO C3aRA = 6 (two-way ANOVA followed by
pairwise comparison).
*p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S4.
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Figure 5. Astroglial NFkB Activation Leads to Aberrant Intraneuronal Calcium
(A) Representative images of GCaMP fluorescence in AAV-GCaMP6s-infected neurons cocultured with WTA or KOA. Scale bar, 50 mm.
(B) Mean GFP fluorescence in cocultured neurons. nWTA = 221 and nKOA = 234 (Student’s t test).
(C) Representative GFP fluorescence in Ctrl or GcKO-derived organotypic hippocampal slice cultures infected with AAV-GCaMP6s. Scale bar, 100 mm.
(D) Quantification of basal GFP fluorescence intensity. n = 65/group (Student’s t test).
(E) Mean GCaMP fluorescence of Ctrl and GcKO slice cultures treated with DMSO, 10 mM C3aRA, or 50 mM BAPTA/AM. nCtrl DMSO = 103, nGcKO DMSO = 104,
nCtrl BAPTA/AM = 60, nGcKO BAPTA/AM = 60, nCtrl C3aRA = 180, and nGcKO C3aRA = 104 (two-way ANOVA followed by Bonferroni post-hoc analysis).
(F) Representative images of MAP2-positive dendritic morphologies in WTA or KOA cocultured neurons treated with DMSO or 1 mMBAPTA/AM for 4 days. Scale
bar, 50 mm.
(G) Sholl analysis of dendritic complexity of WTA or KOA cocultured neurons treated with DMSO or BAPTA/AM. nWTA DMSO = 52, nKOA DMSO = 62, and
nKOA BAPTA/AM = 70 (three-way ANOVA followed by pairwise comparison).
*p < 0.05; **p < 0.01; ***p < 0.001. See also Movie S2.
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An NFkB/C3/C3aR Neuron-Glia Signaling PathwayMurakami et al., 1993; Sayah et al., 2003). Calcium dysregula-
tion could, in turn, initiate a cascade of changes, ultimately
leading to alteration of neuronal morphology and function. We
examined intraneuronal calcium flux in both astrocyte-neuron
cocultures and brain slice cultures with the fluorescent reporter
GCaMP6 (Chen et al., 2013). WT neurons cultured with IkBa
KOAs showed substantially higher baseline calcium levels
than neurons cultured with WT astrocytes (Figures 5A and
5B). We observed a similar elevation in baseline calcium of
GcKO slice cultures compared with littermate controls (Figures
5C and 5D). Baseline calcium levels were restored to normal
both by application of the calcium chelator 1,2-bis(o-aminophe-
noxy)ethane-N,N,N’,N’-tetra-acetic acid-acetoxymethyl ester
(BAPTA/AM) or C3aRA to the cultured slices, suggesting that
calcium dysregulation was downstream of C3aR signaling (Fig-
ure 5E). Finally, normalizing calcium levels with BAPTA/AM (Fig-
ure 5E) rescued dendritic morphology in neurons cultured with
IkBa KO astrocytes (Figures 5F and 5G), placing intraneuronalcalcium in the pathway leading from activated NFkB to altered
neuronal morphology.
The above studies established a novel function of astroglial
NFkB, through C3/C3aR signaling and intraneuronal calcium
regulation, in mediating excitatory synaptic density and dendritic
morphology.We next performed electrophysiological recordings
of excitatory synaptic transmission in neurons cocultured with
WT or IkBa KO astrocytes. We observed miniature excitatory
postsynaptic currents (EPSCs) of larger amplitude in neurons
cultured with IkBa KO astrocytes than with WT astrocytes,
despite no change in frequency, indicating that synaptic strength
was increased by astroglial NFkB/C3 signaling (Figures 6A–6D).
The strength of postsynaptic events is controlled predomi-
nantly by a´-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptor (AMPAR) trafficking (Derkach et al.,
2007; Song andHuganir, 2002; Yamada, 1998), sowe performed
immunocytochemical staining of the AMPAR subunit GluR1 to
examine its surface expression (Figure 6E). Compared with theNeuron 85, 101–115, January 7, 2015 ª2015 Elsevier Inc. 107
Figure 6. C3aR and Intraneuronal Calcium Mediate Excitatory Synaptic Transmission and Surface AMPAR Expression
(A) Example mEPSC traces of WTA or KOA cocultured neurons.
(B) There is increased mEPSC amplitude in KOA neurons compared with WTA controls (Student’s t test).
(C) There are no differences in mEPSC frequency between WTA and KOA cultures (Student’s t test).
(D) mEPSC amplitude fractionation curve of WTA and KOA neurons. nWTA = 13 and nKOA = 14.
(E) Representative images of cocultured WTA and KOA neurons stained against surface GluR1 (Surf. GluR1) and Syn and counterstained with DAPI. The inset
shows enlarged images of the bracketed areas. Scale bar, 10 mm.
(legend continued on next page)
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played higher surface GluR1 intensity both generally at the cell
membrane (Figure 6F) and specifically within synaptophysin-
positive (Syn+) puncta (Figure 6G). In contrast, total GluR1 inten-
sity was not changed, both when measured by immunostaining
of cocultured neurons (Figures S5A and S5B) and by western
blot using lysates from cocultured neurons or GcKO brains (Fig-
ures S5C–S5F). Increased surface GluR1 was further validated
by western blotting of biotinylated cell surface GluR1, which
showed a significant upregulation in neurons cultured with
IkBa KO astrocytes (Figures 6H and 6I). These data suggest
that astroglial NFkB activation results in significant enrichment
of AMPAR at the postsynaptic surface.
Consistent with the prominent rescue of spine density in vitro
and in vivo by C3aR inhibition, application of C3aRA to WT neu-
rons cultured with IkBa KO astrocytes normalized miniature
EPSC (mEPSC) amplitude (Figures 6J and 6K) as well as surface
AMPAR expression (Figures 6L and 6M). Diminished levels of
surface AMPAR were observed within 15 min of C3aRA treat-
ment (Figure S5G), strongly supporting a direct effect of C3/
C3aR signaling. Similar to C3aRA, treatment with BAPTA/AM
also rescued surface GluR1 expression in neurons cultured
with KO astrocytes (Figure 6N), supporting the idea that intra-
neuronal calcium mediates AMPAR trafficking downstream of
astroglial NFkB/C3.
Alterations ofNFkBandC3Levels byAb and in ADBrains
Substantial evidence has implicated dysregulation of NFkB and
calcium homeostasis in Alzheimer’s disease (AD) pathogenesis
(LaFerla, 2002; Mattson, 2007; Mattson and Meffert, 2006). To
explore whether the astroglial NFkB/C3 pathway uncovered
here is induced under conditions relevant to AD, we treated
WT primary astroglial cultures with either the Ab42 peptide or
the control reverse peptide rAb42. Remarkably, treatment with
Ab42, but not rAb42, resulted in prominent translocation of
NFkB from the cytoplasm to the nucleus (Figures 7A and 7B)
and increased expression of C3 mRNA (Figure 7C).
We next examined whether Ab accumulation in vivo was asso-
ciated with C3 elevation and whether inhibiting C3aR signaling
could rescue cognitive impairment in amyloid-bearing mice.
Consistent with the effect of Ab in vitro, we found that C3
mRNA levels were significantly higher in APP/TTA double trans-
genic mice than in TTA single-transgenic controls (Figure 7D;
Jankowsky et al., 2005). We then treated mice with C3aRA or(F) Relative fluorescence intensity of Surf. GluR1 over the whole cell surface (nW
(G) Relative fluorescence intensity of Surf. GluR1 in Syn+ puncta (nWTA = 60,000
(H) Blots of surface GluR1 in cocultured neuronal lysates. Cell surface protein
neurons without biotin incubation. Loading was quantified by blotting with an an
(I) Quantification of the blot in (H) (Student’s t test).
(J) Sample mEPSC traces of WTA or KOA cocultured neurons treated with DMS
(K) Mean mEPSC amplitude of treated neurons. nWTA DMSO = 8, nKOA DMSO = 9,
comparison).
(L) Representative images of surface GluR1 staining with DAPI counterstaining in
(M) Quantification of fluorescence intensity of (L). nWTA DMSO = 35, nKOA DMSO = 31
comparison).
(N) Quantification of Surf. GluR1 fluorescence in cocultured neurons treated w
nWTA BAPTA/AM = 34, and nKOA BAPTA/AM = 31 (Two-way ANOVA followed by pairw
*p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S5.vehicle (DMSO) for 3 weeks before testing their performance
in a Morris water maze (MWM) and radial arm water maze
(RAWM) (Fowler et al., 2014). Treatment was initiated at an
age when cognitive impairments are already manifested, and,
consistent with past characterization of this model, vehicle-
treated APP/TTA mice took more days of training than TTA con-
trols to reach criterion performance in the MWM and made
more working memory errors in the RAWM (Figures 7E and
7F). Although C3aRA treatment did not change the behavior of
control TTA mice, it improved the performance of APP/TTA
mice to control levels in both tasks (Figures 7E and 7F).
To further assess whether this pathway is perturbed in human
disease, we performed a biochemical analysis of NFkB, IkBa,
and C3 in postmortem AD brains and age-matched nonde-
mented controls. Both NFkB, measured by nuclear p65 levels
(Figure 7G), and its targets IkBa (Figures 7H and 7I) and C3 (Fig-
ure 7J) were significantly higher in AD samples than in controls.
Although the sequence of events leading to upregulation of
NFkB signaling in AD remains to be elucidated, our findings over-
all support a role for altered astrocytic IkBa/NFkB signaling in AD
pathophysiology.
DISCUSSION
Loss-of-function studies have revealed essential roles of NFkB
and the complement system in neuronal function and synapse
elimination during development (Boersma et al., 2011; Koo
et al., 2010; Meffert et al., 2003; Stevens et al., 2007), However,
these pathways are known to be activated under pathological
conditions. Very few genetic gain-of-function models have
been generated (Gerondakis et al., 2006; Hanafusa et al.,
2002), and those that exist have been limited to ectopic overex-
pression, which may not be appropriate for understanding these
pathways in pathological conditions. Furthermore, little is known
about cell type-specific regulation and crosstalk between the
two pathways. Here we used Cre-directed IkBa deletion to
create mice in which NFkB was selectively activated in either
neurons or astroglia and combined the genetic model with
neuron-astrocyte cocultures to study the consequence of aber-
rant NFkB signaling in the brain. We reveal that (1) astroglia, not
neurons, are the main source of IkBa-dependent NFkB activa-
tion; (2) complement factor C3 is an astroglial NFkB target that
engages neuron-glia interaction through neuronal C3aR; (3)
aberrant elevation of NFkB/C3/C3aR signaling alters dendriticTA = 20 and nKOA = 19, Student’s t test).
and nKOA = 45,000, Student’s t test).
samples were prepared by surface biotinylation. Ctrl lanes are samples from
ti-g-tubulin antibody in cell lysates before neutravidin pull-down.
O or 1 mM C3aRA for 4 days.
nWTA C3aRA = 12, and nKOA C3aRA = 17 (two-way ANOVA followed by pairwise
WTA or KOA neurons treated with DMSO or C3aRA. Scale bar, 10 mm.
, nWTA C3aRA = 33, and nKOA C3aRA = 37 (two-way ANOVA followed by pairwise
ith DMSO or 1 mM BAPTA/AM for 15 min. nWTA DMSO = 29, nKOA DMSO = 24,
ise comparison).
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Figure 7. Activation of NFkB/C3 in AD and the Beneficial Effect of the C3aR Antagonist
(A) p65 andGFAP double-staining of primary wild-type astroglial cultures incubated with Ab42 peptide showing p65 nuclear translation induced by Ab42. Reverse
Ab42 peptide (rAb42) was used as a negative control. Scale bar, 20 mm.
(B) Quantification of the nuclear/cytoplasmic p65 ratio (n = 50 cells/group, Student’s t test).
(C) qPCR measurement of C3 mRNA expression in astroglial cultures treated with Ab42 or rAb42 (n = 3/group, Student’s t test).
(D) C3 mRNA expression in the APP/TTA AD mouse model compared with the control TTA mice (nTTA = 6 and nAPP/TTA = 7, Student’s t test).
(E) Rescue of Morris water maze deficits in APP/TTA mice by C3aRA (nTTA DMSO = 7, nAPP/TTA DMSO = 8, nTTA C3aRA = 6, and nAPP/TTA C3aRA = 7; two-way ANOVA
followed by pairwise comparison).
(F) Rescue of radial armwater maze deficits in APP/TTAmice by C3aRA (nTTA DMSO = 7, nAPP/TTA DMSO = 8, nTTA C3aRA = 5, and nAPP/TTA C3aRA = 7; two-way ANOVA
followed by pairwise comparison).
(G) ELISA measurement of NFkB subunit p65 in nuclear fractions of human brain lysates from control subjects (Ctrl) and AD patients (nCtrl = 7 and nAD = 8,
Student’s t test).
(H) Western blotting of IkBa levels in Ctrl and AD human total protein lysates. Neuron-specific enolase (NSE) was used as a loading control.
(I) Quantification of the blots in (H) (Student’s t test).
(J) C3 protein concentration in total protein lysates from control and AD brain samples (nCtrl = 7 and nAD = 8, Student’s t test).
*p < 0.05; **p < 0.01; ***p < 0.001. See also Table S1.
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nal calcium dysregulation; and (4) antagonizing C3aR restores
morphological and functional defects resulting from NFkB hy-
peractivation. Our studies therefore reveal a critical role for the
astroglial IkBa/NFkB loop in neuronal homeostasis through a
novel neuron-glia signaling pathway that has direct relevance
for AD pathogenesis. Both NFkB and C3 are induced in astroglia
by exposure to Ab and are upregulated in APP transgenic mice
and human AD tissue. This pathway may also provide a potential
entry point for therapeutic intervention because short-termC3aR
inhibition produced nearly complete rescue of multiple cognitive
deficits in APP transgenic mice.
NFkB/C3-Mediated Neuron-Glia Signaling in Neuronal
Homeostasis
NFkB has been shown to regulate neuronal survival and function
(Ahn et al., 2008; Kaltschmidt et al., 2006; Kassed et al., 2002;
Levenson et al., 2004; Meffert et al., 2003). These activities
have been attributed, at least in part, to the presence of consti-
tutive NFkB activity in neurons (Blondeau et al., 2001; Kaltsch-
midt et al., 1993, 1994, 1995, 2000). However, recent studies
by us and others reported that, comparedwith astroglia, neurons
exhibit negligible NFkB activity (Lian et al., 2012; Mao et al.,
2009). Consistent with this assessment, we found that both
IkBa and C3 are expressed at substantially higher levels in astro-
glia compared with neurons under both basal and TNF-a-stimu-
lated conditions. Furthermore, only astroglial, but not neuronal,
C3 is regulated in an NFkB-dependent manner. Therefore,
although it remains possible that other IkBs may regulate
neuronal NFkB, our results provide strong support for the hy-
pothesis that IkBa is a critical mediator of NFkB activity in astro-
glia but not in neurons.
Although this study is focused on addressing the pathological
consequences of NFkB activation, the astroglial NFkB/C3-medi-
ated neuron-glia interaction may also mediate neuronal and
synaptic function under physiological conditions. For example,
during early postnatal development, complement proteins,
including C3 and C1q, are highly expressed in the brain (Stevens
et al., 2007), and C3aR has been reported to regulate the migra-
tion and differentiation of neuronal progenitor cells (Rahpeymai
et al., 2006; Shinjyo et al., 2009). Interestingly, NFkB is also tran-
siently activated during neural development (Guerrini et al., 1997;
Simakajornboon et al., 2001), making it tempting to speculate
that NFkB serves the same function in development as in the
adult brain, and, in both cases, it indirectly controls neural func-
tion by regulating the onset and degree of complement activity in
astroglia.
Previous studies have shown that glia-derived TNF-a controls
neuronal synaptic strength (Beattie et al., 2002) and mediates
synaptic scaling during activity blockade (Stellwagen and Mal-
enka, 2006). In this study, we found that TNF-a increases C3
mRNA expression and that enhanced astroglial NFkB/C3/
C3aR signaling promotes AMPAR membrane localization to in-
crease synaptic strength. Taken together, these findings raise
the possibility that C3/C3aR neuron-glia signaling may act
downstream of TNF-a to promote synaptic plasticity.
In addition to astrocytes, NFkB and complement proteins are
also abundantly expressed inmicroglia (Fa¨rber et al., 2009; Lucinand Wyss-Coray, 2009; Sheppard et al., 2011; Wyss-Coray and
Rogers, 2012; Zhang et al., 2014). Although we provide evidence
for direct neuron-astroglia interaction, it is important to note that
there may exist a parallel neuron-microglia interaction mediated
through the same NFkB/complement pathway. Furthermore,
astrocyte-derived complement proteins may also signal micro-
glial activation, leading indirectly to neuronal dysfunction
through a myriad of microglial-derived factors. Crosstalk be-
tween microglia, astroglia, and neurons has long confounded
elucidation of their individual roles in neuroinflammatory dam-
age. The combination of genetic and coculture approaches
we used here to study neuron-astroglia interactions may provide
a useful road map for future work on the neuron-microglia
relationship.
NFkB/C3-Mediated Neuron-Glia Signaling in
Alzheimer’s Disease
Activation of NFkB and complement are common features in AD
and other neurological conditions. However, it has been difficult
to establish whether NFkB and complement activation cause
neuronal dysfunction or are a consequence of neuronal injury
and neuroinflammation. In this study, we identified C3 as a
bona fide astroglia-specific NFkB target that is both necessary
and sufficient to produce neuronal impairment through C3aR
and intraneuronal calcium signaling. Our data are consistent
with the notion that calcium dysregulation is a major cause of
defective synaptic function in multiple neurodegenerative dis-
eases, AD in particular (LaFerla, 2002; Mattson, 2007). Overall,
we propose a model whereby Ab evokes astroglial NFkB activa-
tion and release of C3, which, through neuronal C3aR and intra-
neuronal calcium, increases synaptic excitation and disrupts
dendritic morphology, the combination of which leads to
network dysfunction. This model links Ab with synaptic defects
and neuronal hyperexcitability through a novel neuron-glia
signaling pathway and places the astroglial IkBa/NFkB regu-
latory loop and complement activation as integral events in AD
pathogenesis.
C3aR Antagonists as Therapeutic Targets for AD
Our findings that the astroglial NFkB/complement levels are
inducible by Ab, that this pathway is elevated in AD mouse
models and patient brain samples, and that inhibition of C3aR
ameliorates the behavioral deficits in the AD mouse model sup-
port the notion that inhibiting this pathway may be therapeuti-
cally beneficial. This assessment is further supported by past
studies documenting a general neuroprotective effect by block-
ing complement activation (Fonseca et al., 2009; Leinhase et al.,
2006; Woodruff et al., 2008). As a G protein-coupled receptor,
C3aRmay prove to be highly tractable for pharmaceutical inhibi-
tion, and, importantly, mice with complete C3aR deletion are
overtly normal (Humbles et al., 2000). Therefore, C3aR may
make an attractive target for intervention in AD.
EXPERIMENTAL PROCEDURES
Mouse Models and Manipulations
The mouse lines and behavioral protocols are described in the Supplemental
Experimental Procedures.Neuron 85, 101–115, January 7, 2015 ª2015 Elsevier Inc. 111
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taxic injection of 1 ml AAV-GFP (Penn Vector Core, catalog no. AV-9-PV0101,
1 3 1013 transduction unit (TU)/ml) into the mouse cortex (+2.0 mm anterior-
posterior, ± 3.0 mm medial-lateral, 1.5 mm dorsal-ventral). Three days after
stereotaxic injection, mice were injected intraperitoneally (i.p.) with 0.5%
DMSO or C3aRA (1 mg/kg) three times per week (Mondays, Wednesdays,
and Fridays) for 3 weeks. GcKO mice and controls at 9 or 15 months were
used for behavioral testing and LTP recording. The APP/TTA mice and the
TTA controls were tested at 8 months of age after 3 weeks of C3aRA or vehicle
treatment.
All animal procedures were performed in accordance with NIH guidelines
and with the approval of the Baylor College of Medicine Institutional Animal
Care and Use Committee.
Primary Cell Culture, Neuron-Astroglia Coculture, Slice Culture, and
Treatment
Primary neurons were prepared from postnatal day 0 pups using a protocol
described previously (Lian et al., 2012). Primary astroglia were cultured using
the same protocol but with astroglial medium (DMEM with 10% fetal bovine
serum). Contaminating cells on top of the astroglia monolayer were removed
by overnight shaking at 220 rpm at 37C. For coculture, astroglial cells were
seeded on Matrigel-coated cell culture inserts (Costar, catalog nos. 3450
and 3470) and transferred to day in vitro (DIV) 1 primary neurons. We supple-
mented 5 mM cytosine arabinoside to curb glia proliferation. Cocultures were
maintained for 2 weeks before immunostaining or recording. Two independent
cultures were used for all in vitro experiments.
The NFkB inhibitor JSH23 (20 mM, Calbiochem, catalog no. 481408) and
50 ng/ml TNF-a (Sigma, catalog no. T0157) were added to astroglial cultures
for 20 hr for the inhibitor assay. BAPTA/AM (Calbiochem, catalog no.
196419), C3 (Millipore, catalog no. 204885), C3aRA (Calbiochem, catalog
no. SB290157), or C5aRA (Calbiochem, catalog no. W54011) at different
dosages (specified in the figure legends) were added to cultures at DIV10 for
long-term or at DIV14 for short-term incubation. AAV-GCaMP6s (Penn Vector
Core, catalog no. AV-1-PV2824) were added to neuronal cultures at a multi-
plicity of infection of 2.41 3 106 immediately after neurons were seeded and
removed when media was replaced. Synthetic Ab42 (Invitrogen, catalog no.
03-111) and rAb42 (Sigma, catalog no. SCP0048) peptides were prepared
as described previously (Stine et al., 2003) and used at 100 nM on primary
astroglia for 20 min before fixation for staining or for 20 hr before cell harvest
for quantitative PCR (qPCR).
Slice cultures were prepared following the protocol described in Gogolla
et al. (2006). One microliter AAV-GCaMP6s virus at a titer of 2.41 3 1013 TU/
ml was added to the medium immediately before slices were plated and
removed when the medium was replaced.
Quantitative RT-PCR and ELISA
cDNA was synthesized and analyzed as described previously (Yang et al.,
2009). The primer sequences were as follows: 50-AAGCATCAACACACC
CAACA-30 (C3 forward), 50-CTTGAGCTCCATTCGTGACA-30 (C3 reverse),
50-AATGTGTCCGTCGTGGATCTGA-30 (glyceraldehyde 3-phosphate dehy-
drogenase [GAPDH] forward), and 50-GATGCCTGCTTCACCACCTTCT-30
(GAPDH reverse).
C3 levels in brain lysates were determined using a mouse C3 ELISA kit
(Genway, catalog no. GWB-7555C7). Quantification of the relative nuclear
p65 level was determined using a Cayman NFkB (p65) transcription factor
assay kit (catalog no. 10007889).
Immunostaining and Image Processing and Quantification
Fixed primary neurons were washed, permeabilized, blocked, and incubated
in primary antibody solution overnight at 4C (mouse anti-MAP2, Millipore,
catalog no. MAB3418, 1:2,000; rabbit anti-synaptophysin, Synaptic Systems,
catalog no. 101 002, 1:2,000; mouse anti-GluR1, Millipore, catalog no.
MAB2263, 1:500; rabbit anti-VGluT1, Synaptic Systems, catalog no. 135
302, 1:1,000; mouse anti-VGAT, Synaptic Systems, catalog no. 131 011,
1:1,000; mouse anti-GFAP, Millipore, catalog no. MAB3402, 1:2,000; and
rabbit anti-p65, Cell Signaling Technology, catalog no. 8242, 1:100). For
immunostaining of surface GluR1, neurons were incubated with diluted112 Neuron 85, 101–115, January 7, 2015 ª2015 Elsevier Inc.anti-GluR1 antibody (1:100) at 37C for 5 min before fixation. Coverslips
were mounted in DAPI solution after washing and secondary antibody
incubation.
Synapses were recognized as puncta positive for presynaptic markers (Syn,
VGluT1, or VGAT) in proximity to the dendritic marker MAP2. NeuronJ (Meijer-
ing et al., 2004) and advanced Sholl analysis plug-ins of ImageJ were used to
calculate total dendritic length and dendritic complexity. ImageJ was used to
measure GluR1 fluorescent intensity over the whole cell surface, blots of sur-
face GluR1, and synaptic density, which equal the number of positive puncta
divided by the length of the dendrite. Adobe Photoshop was used to measure
GluR1 expression in Syn+ puncta using z stack images of both GluR1 and
Syn channels. Spine density was calculated as the number of spines divided
by dendritic length using the 3D renderings of AAV-GFP-infected neuronal
dendritic spines reconstructed by Neurolucida (MBF Bioscience) (See
Movie S1). Classification and quantification of the frequency and density of
different spine types were performed using IMARIS software (Bitplane).
AAV-GCaMP6s-infected neurons and slices were imaged using an EVOS fluo-
rescence microscope (AMG) at 103 magnification. Images were processed
by Adobe Photoshop to measure GFP fluorescence.
Electrophysiology
Hippocampal cultures were transferred to a recording chamber perfused with
artificial cerebrospinal fluid (ACSF) solution containing 1 mM tetrodotoxin and
100 mM picrotoxin. mEPSCs were recorded using electrodes (borosilicate
glass, WPI) filled with whole-cell solution with a resistance of 3–6 MU.
Field recordings of Schaffer collateral LTP was performed as described
previously (Peethumnongsin et al., 2010; Polito et al., 2014). Stimulation
of Schaffer collaterals from the CA3 region was performed with bipolar elec-
trodes, whereas borosilicate glass capillary pipettes filled with recording
ACSF (resistances of 2–3.5 MU) were used to record field excitatory postsyn-
aptic potentials (fEPSPs) in the CA1 region.
Human Brain Tissues
Frozen frontal cortex brain tissues from control subjects and AD patients eval-
uated clinically and neuropathologically were obtained from the Oregon Brain
Bank at Oregon Health and Science University. The demographic information
of the samples is listed in Table S1.
Statistics
All data are presented as mean ± SEM. Pairwise comparisons were analyzed
using a two-tailed Student’s t test, whereas a one-way, two-way, or three-way
ANOVA followed by Bonferroni post hoc analysis, pairwise comparison, or
planned means comparison was used for multiple comparisons. p values of
less than or equal to 0.05, 0.01, and 0.001 were considered statistically signif-
icant. p values of higher than 0.05 were considered nonsignificant (NS).
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The GEO accession number for the microarray data derived from the hippo-
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